Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 6,888 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 6,888 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.05, for a total transaction of $241,424.40. Following the sale, the director owned 345,879 shares of the company’s stock, valued at $12,123,058.95. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The shares were sold at an average price of $30.32, for a total value of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The shares were sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Stock Down 1.8%

Shares of NASDAQ PHVS opened at $33.95 on Thursday. Pharvaris N.V. has a 12 month low of $17.05 and a 12 month high of $35.90. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -10.68 and a beta of -2.34. The business has a fifty day simple moving average of $30.90 and a 200-day simple moving average of $28.21.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts expect that Pharvaris N.V. will post -3.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Citigroup restated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Morgan Stanley upped their price target on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $49.64.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP purchased a new stake in Pharvaris in the 3rd quarter worth approximately $43,282,000. Paradigm Biocapital Advisors LP increased its stake in shares of Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Pharvaris in the third quarter worth $15,613,000. Commodore Capital LP raised its holdings in shares of Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. raised its holdings in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, which can support investor confidence in the company’s longer-term outlook. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
• Positive Sentiment: PHVS recently reached a new 1-year high, suggesting momentum has been strong heading into today’s trading. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
• Neutral Sentiment: The company’s insider activity included multiple sales by Anne Lesage and Director Johannes Gerardus Chri Schikan on June 29-30, totaling a sizable reduction in their holdings. While insider sales do not always signal a fundamental problem, they can weigh on sentiment because investors may view them as a sign of limited near-term upside. SEC insider filing

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.